Skip to main content

Table 2 Study measures

From: Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial

   Baseline pre-intervention Post-intervention Follow-up (3 and 6 months after AET intake)
Inclusion criteria Interview measures    
  Structured psychiatric interview (mini-dips) x1   
  Demographic and medical data x   
  Questionnaire measures    
Primary + Secondary Outcomes Physical symptoms and side effects + coping (GASE+Coping) x   x
  Quality of life (EORTC QLQ C30 & BR23) x   x
  Adherence (MARS-D), Adherence Intention x x x
Expectation Scales Expected side effects + expected coping (GASE-Expect + * *Coping) x x x
  Illness beliefs (IPQ-B) x x x
  Beliefs about medicines (BMQ-D) x x x
Process Variables Fear of progression (PA-F-K) x x x
  Anxiety and depression (HADS) x x x
  Knowledge hormone receptor x x x
  Treatment evaluation   x2  
Control Variables Somatosensory amplification (SSAS) x   
  Prior experiences with endocrine treatment x   
  Partnership quality x   
  Additional medication x   x
  1. Notes:
  2. 1The psychiatric interview is conducted prior to the measurement to check the inclusion criteria.
  3. 2Completed after every therapy session in the intervention groups only.